Ranolazine in Ischemic Cardiomyopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
CardiomyopathyChest PainDyspnea
Interventions
DRUG

Ranexa

1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

DRUG

Placebo

1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Trial Locations (1)

52803

Midwest Cardiovascular Research Foundation, Davenport

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Midwest Cardiovascular Research Foundation

OTHER

NCT01345188 - Ranolazine in Ischemic Cardiomyopathy | Biotech Hunter | Biotech Hunter